News | June 05, 2024
AstraZeneca completes acquisition of Fusion Pharmaceuticals
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Additional data from APPRAISE ATP trial reinforce modular therapy approach
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
the campaign emphasizes the brand's reliability and effectiveness in providing timely relief
Subscribe To Our Newsletter & Stay Updated
